Skip to main content
Download PDF
  • Traitement Anticancereux, Fonction de Reprodution et Sexualtite
  • Published:

Protection gonadique contre les effets iatrogènes des traitements anticancéreux: données expérimentales

Protection of the testis against side effects of cancer therapy: experimentation in animal

Andrologie volume 5, pages 498–503 (1995)Cite this article

Resume

Les agents cytotoxiques utilisés dans les thérapies anticancéreuses induisent de graves et durables dysfonctionnements de la fonction de reproduction chez des individus jeunes. En dehors de mesures prophylactiques (cryopréservation des spermatozoïdes avant traitements, les écrans en cas d'irradiation et l'utilisation d'agents moins cytotoxiques pour la spermatogenèse), l'utilisation d'agents protecteurs s'avère nécessaire. Expérimentalement de nombreux agents anti-oxydants et des hormones de natures diverses ont été utilisés afin de tenter de préserver ou de limiter les effets délétères des agents antimitotiques. Parmi ceux-ci, certains analogues de la GnRH, la FSH et des stéroïdes, dont l'association d'acétate de médroxyprogestérone (MPA) et testostérone (T), ont fait l'objet d'un nombre important d'études chez l'animal, ces études ayant parfois produit des résultats très encourageants. Les progrès réalisés dans l'expérimentation animale devraient, dans un délai pas trop lointain, ouvrir la voie à des transferts à l'homme.

Abstract

The cytotoxic agents used in cancer therapy cause serious and long lasting side effects on spermatogenesis in young male patients. In absence of prophylactic measures (cryoconservation of Spermatozoa prior to therapy; lead shields during radiation therapy; drugs less damaging to spermatogenesis), the use of protective agents is necessary. Numerous antioxydants and a variety of hormones have been experimented in attempts to limit the deleterious effects of antimitotic drugs. Major animal studies have been conducted into œrtain GnRH analogs, FSH steroïds, and in particular the combination of Medroxyprogesterone Acetate + Testosterone, leading to encouraging results.

Progress in animal experimentation should, within the near future, allow clinical trials in humans.

References

  1. ASHBY R., DAVIS L., DEWHURST B.B., ESPINAL R., PENN R.N., UPSHALL D.G.: Aspects of the teratology of cyclophosphamide (NSC-26271) Cancer Treat. Rep. 1976, 60: 477.

    PubMed  CAS  Google Scholar 

  2. AUROUX M., DULIOUST E.: Cylophosphamide in the male rat: behavioral effects in the adult offspring. Behav. Brain. Res., 1985, 16: 25–36.

    Article  PubMed  CAS  Google Scholar 

  3. AUROUX M., DULIOUST E., NAWAR N., YACOUB B.: Antimitotic drugs (Cyclosphosphamide and Vinblastine) in the male rat: deaths and behavioral abnormalities in the offspring. J. Androl. 1986, 7: 378.

    PubMed  CAS  Google Scholar 

  4. CATTANACH B.M., RASBERRY C.: Genetic effects of combined chemical x-ray treatments in male mouse germ cells. Int. J. Radiat. 1987, 51: 985.

    Article  CAS  Google Scholar 

  5. DELIC J.I., BUSH C., PECKHAM M.J.: Protection from procarbazine-induced damage of spermatogenesis in the rat by androgen. Cancer Res., 1986, 46: 1909.

    PubMed  CAS  Google Scholar 

  6. DELIC J.L., HARWOOD J.R., STANLEY J.A.: Time dependence for the protective effect of androgen from procarbazine-induced damage to rat spermatogenesis. Cancer Res. 47: 1344.

  7. DELIC J.I.: Protection of spermatogenesis during cancer chemotherapy. Arch. Androl. 1987, 18: 211.

    Article  PubMed  CAS  Google Scholar 

  8. DULIOUST E., RADIGUE C., VELEZ DE LA CALLE J.F., JÉGOU B., SOUFIR J.C., AUROUX M.: Traitement cytostatique chez le mâle: conséquences sur la descendance et effet protecteur d'un traitement hormonal préalable. C.R. Acad. Sci. France, 1989, 111. 309, 137.

    Google Scholar 

  9. GLODE L.M., ROBINSON J., GOULD S.F.: Protection from cyclophosphamideinduced testicular damage with an analogue of Gn-RH. Lancet i, 1981, 1132.

    Article  Google Scholar 

  10. HALES B.F.: Modification of the teratogenicity and mutagenicity of cyclophosphamide with thiol compounds. Teratology, 1981, 23: 373.

    Article  PubMed  CAS  Google Scholar 

  11. HORSTMAN M.G., MEADOWS G.G., YOST G.S.: Cancer Res. 47: 1547.

  12. JÉGOU B., VELEZ DE LA CALLE J.F., BAUCHÉ F.: Protective effect of medroxyprogesterone acetate plus testosterone against radiation induced damage to the productive function of male rats and their offspring Proc. Natl. Acad. Sci. 1991, 8710.

  13. JOHNSON S.A., GOLDMAN J.M., HAWKINS D.F.: Pregnancy after chemotherapy for Hodgkin's disease. Lancet, 1979, 2: 93.

    Article  PubMed  CAS  Google Scholar 

  14. KURDOGLU B., WILSON G., PARCHURI N., YE W.S., MEISTRICH M.: Protection from radiationinduced damage to spermatogenesis by hormone treatment. Radiat. Res. 1993, 139: 97.

    Article  Google Scholar 

  15. LE GRANDE C.E.: Relation effects. In: The Testis, eds Johnson A.D., Gomez W.R. and Vandemark N.L., vol III (Academic Press, New York, Chap 9, pp 333).

  16. LI F.P., JAFFE N.: Progeny of chilhood cancers survivors. Lancet, 1974, 2: 704.

    Google Scholar 

  17. MARMOR D., JOYE N., TAILLEMITE J.: La qualité du conceptus après maladie oncologique, l'experience humaine. Bull. Salf, 1989, 3: 40.

    Google Scholar 

  18. MEISTRICH M.L., FINCH M.V., HUNTER N., MILAS L.: Protection of spermatogonial survival and testicular function by WR-2721 against high and low doses of radiation. Int. J. Radiat. Oncol. Biol. Phys., 1984, 10: 2099.

    PubMed  CAS  Google Scholar 

  19. MILAS L., HUNTER N., REID B.O., THAMES Jr H.D.: Protective effects of S-2-(3Aminopropylamino) ethyl-phosphorothioic acid against radiation damage of normal tissues and a fibrosarcoma in mice. Cancer Res 1982, 42, 1888.

    PubMed  CAS  Google Scholar 

  20. PARCHURI N., WILSON G., MEISTRICH M.: Protection by gonadal steroid hormones against PZB-induced damage to spermatogenic function in LBNF1 hybrid rats. J. Androl., 1993, 14, 257.

    PubMed  CAS  Google Scholar 

  21. SCHILSKY R.L., LEWIS B.J., SHERINS R.J., YOUNG R.C.: Gonadal dysfunction in patients receiving chemotherapy for cancer. Am. Intern. Med., 1980, 93: 109.

    CAS  Google Scholar 

  22. SENTURIA Y.D., PECKHAM C.S., PECKHAM M.J.: Children fathered by man trated for testicular cancer. Lancet, 1985, 5: 766.

    Article  Google Scholar 

  23. SHERINS R.J., DE VITA V.T.: Effect of drug treatment for lymphoma on male reproductive capacity, Ann. Intern. Med. 1973, 79: 216.

    PubMed  CAS  Google Scholar 

  24. TRASLER J.M., HALES B.F., ROBAIRE B.: Chronic low-dose cyclophosphamide treatment of adult male rats effect on fertility, pregnancy outcome, and progeny. Biol. Reprod. 1986, 34, 275, 39.

    Google Scholar 

  25. TRASLER J.M., HALES B.F., ROBAIRE B.: Paternal cyclophosphamide treatment of rat causes fetal loss and malformations without affecting male fertility. Nature, 1985, 316: 144.

    Article  PubMed  CAS  Google Scholar 

  26. TRASLER J.M., HALES B.F., ROBAIRE B.: A time-course study of chornic paternal cyclophosphamide treatment in rats: effects on pregnancy outcome and the male reproductive and hematologic systems. Biol. Reprod. 1987, 37: 317.

    Article  PubMed  CAS  Google Scholar 

  27. Van ALPHEN M.M.A., van DE KANT H.J.G., de ROOIJ D.G.: Protection from radiationinduced damage of spermatogenesis in the rhesus monkey (Macaca mulata) by FSH. Cancer Res. 1989, 49, 533.

    PubMed  Google Scholar 

  28. Van VLIET J., BOOTSMA A.L., van PEPERZEEL H.A., SCHIPPER J., WENSING C.J.G.: Protective effect of hypoxia in the ram testis during single and split-dose X-irradiation. Radiother. Oncol., 1988, 13, 9.

    Article  PubMed  Google Scholar 

  29. Van VLIET J., de ROOIJ D., WENSING C., BOOTSMA A.: Protection of spermatogenesis against cytotoxic effects of two chemotherapeutic drugs by temporary testicular blood flow interruption in the ram. Andrologia, 1993, 25: 251.

    Article  PubMed  Google Scholar 

  30. VELEZ de la CALLE J.F., SOUFIR J.C., CHODORGE F., KERCRET H., BOISSEAU C., JÉGOU B.: Reproductive effects of anti-cancer drug procarbazine in male rats at different ages. J. Reprod. Fertil., 1988, 84, 51.

    PubMed  CAS  Google Scholar 

  31. VELEZ de la CALLE J.F., DE QUEIROZ F., GARNIER D.H., KERCRET H., FOLLIOT R., JEGOU B.: Reproductive effects of anti-cancer drug cyclophosphamide in male rats at different ages. Arch Androl., 1989, 22: 101.

    Article  Google Scholar 

  32. VELEZ de la CALLE J.F., BEN HASSEL M., JÉGOU B.: Radiation and testicular function: effects of x-rays and protection by a contraceptive regime. In: IVth International Congress of Andrology. Edited by Monduzi Editore Bologne, 1989, pp 235.

  33. VELEZ de la CALLE J.F., JÉGOU B.: Prevention by a contraception of anti-cancer drug induced sterility and genotoxicity in male rats. Cancer Res. 1990, 50: 1308.

    PubMed  CAS  Google Scholar 

  34. VELEZ de la CALLE J.F., BAUCHÉ F., JÉGOU B.: Protection de la fertilité mâle lors des traitements anticancéreux: I'expérience animale. Progrès en Urol. 1992, 2, 110.

    CAS  Google Scholar 

  35. VELEZ de la CALLE J.F., JÉGOU B.: Protection by steroids against cyclophosphamide-induced damage to the reproductive function of male rats. Int. J. Androl. 1995, sous presse.

  36. VELEZ de la CALLE J.F., BEN HASSEL M., JÉGOU B.: Hypothermia protects rat spermatogenesis against a sterilizing dose of gamma rays. 85th Annual Meeting of the Am. Ass. Cancer Res., 1994, April 10–13, San Francisco.

Download references

Author information

Authors and Affiliations

  1. Unité F.l.V., Clinique Pasteur, 34, rue du Moulin à Poudre, 29200, Brest, France

    J. F. Velez De La Calle

  2. Centre de Lutte contre le Cancer Eugène Marquis, Rue de la Bataille Flandre-Dunkerque, BP 6279, 35062, Rennes Cedex, France

    M. Ben Hassel

  3. GERM-INSERM U. 435, France

    B. Jegou

  4. GERM-INSERM U. 435, Université de Rennes 1, Campusde Beaulieu, 35042, Rennes Cedex, France

    B. Jegou

Authors
  1. J. F. Velez De La Calle
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Ben Hassel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B. Jegou
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Velez De La Calle, J.F., Hassel, M.B. & Jegou, B. Protection gonadique contre les effets iatrogènes des traitements anticancéreux: données expérimentales. Androl. 5, 498–503 (1995). https://doi.org/10.1007/BF03034534

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03034534

Mots Clés

Key words

Basic and Clinical Andrology

ISSN: 2051-4190